

Comprehensive Genomic Profiling with DNA and RNA

FoundationOne®Heme is a laboratory developed, comprehensive genomic profiling test that combines DNA and RNA sequencing for patients with hematologic malignancies, sarcomas, or solid tumors where RNA sequencing is desired.



Our Comprehensive Gene Panel Analyzes Over

400 DNA genes

200 RNA genes

to **detect all four main classes of genomic alterations**, including sensitive identification of translocations and fusions.

Includes results from genomic signatures:

- Tumor Mutational Burden (TMB)
- Microsatellite Instability (MSI)



Valuable Insights


FoundationOne Heme can be used by physicians to **identify targeted therapy options, detect alterations in prognostic genes, and sub-classify sarcoma diagnoses.**



Medicare Covered

National coverage determination for qualifying Medicare patients diagnosed with a myeloid malignancy or suspected myeloid malignancy.¹

FoundationOne Heme interrogates both DNA and RNA



Gene fusions and rearrangements are hallmarks of certain hematologic malignancies and sarcomas. By **combining DNA and RNA sequencing, FoundationOne Heme can detect these alterations.**²

Genomic testing that can be integrated into your practice workflow



MULTIPLE SAMPLE TYPES ACCEPTABLE FOR TESTING

FoundationOne Heme is validated on multiple sample types—peripheral whole blood, bone marrow aspirate, extracted DNA/RNA, and formalin-fixed paraffin-embedded (FFPE) tissue—with a minimum tumor/lesional content of 20% for optimal analysis.



ON-CALL CLINICAL SUPPORT

Discuss patient results with our Medical Affairs team. This robust on-call program is covered by internal experts such as the Medical Science Liaison (MSL) team or by internal and external oncologists who are subject matter experts and consultants for Foundation Medicine.



ONLINE PORTAL

The Foundation Medicine Online Portal allows you to place orders digitally, track in-progress tests and view patient reports.

To order a test, go to www.foundationmedicine.com/order

References

1. Qualifying Medicare and Medicare Advantage members have coverage of FoundationOne®Heme under the MoDx Local Coverage Determination (LCD) for Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38047)
2. He J, et al. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. *Blood*. 2016 Jun 16;127(24):3004-3014.

FoundationOne®Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Heme, please see its Technical Specifications at foundationmedicine.com/heme.